Indication: Urothelial Carcinoma
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy
Untreated locally advanced or metastatic
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: F. Hoffmann-LaRoche Ltd.
Email for more information: GU-NCIResearch@nortonhealthcare.org